Judicial tension: drug litigation intensifies after the MSP's appeal to the Moratorium case

By Agustin Miller

The Uruguayan health system is going through one of its most high-profile and complex litmus tests of the year 2026. drug litigation took on a new dimension this May 4, when the Ministry of Public Health (MSP) formalized its intention to appeal the ruling that ordered it to immediately and free of charge supply the medicine Opdualgar to the renowned virologist Gonzalo Moratorio. The scientist, a key player in the management of the pandemic years ago, today faces a grade 4 astrocytoma in the left parietal lobe, an extremely aggressive oncological pathology.

The first instance court ruling had been categorical: the State had to deliver the medication within a maximum period of 24 hours to guarantee the continuity of the treatment prescribed by the doctor. However, the Ministry's decision to file an appeal momentarily suspends this obligation, transferring the legal battle to an appeal court that must decide on the immediate future of the patient and the precedent for the system.

Drug Litigation: The Clash Between Equity and Individual Law

The MSP's position does not focus on the clinical validity of the case, but on the preservation of the guiding principles of the National Integrated Health System. According to sources from the portfolio, the appeal seeks to avoid individual exceptions that could fracture the pillars of social justice and equal conditions for all users. For the authorities, accessing each judicial demand without an analysis of financial sustainability would put at risk the State's ability to serve the rest of the population.

This drug litigation It is framed in a context of growing judicialization of medicine in Uruguay. During the past year, the MSP had to face more than two thousand lawsuits for similar situations, and the trend so far in 2026 indicates that hundreds of people continue to resort to the courts to obtain therapies that are not included in the Therapeutic Medication Formulary (FTM).

The impact on health policy and public opinion

The Minister of Health has maintained a firm line regarding the sustainability of the system, warning that protection resources, although legitimate under the constitutional framework, generate financial pressure that forces highly complex financing policies to be reviewed. The Moratorium case, due to the patient's public relevance, has catalyzed a national debate about whether current protocols are agile enough to respond to life-or-death needs.

The scientist's defense argues that the right to life and health are fundamental and must prevail over budgetary restrictions. With a period of three days to substantiate the appeal, the Moratorium legal team is preparing to refute the state's arguments, while time runs against the evolution of the disease.

Next steps in Uruguayan justice

The resolution made by the Court of Appeals will be closely watched by patient organizations and medical groups. Not only will it define Moratorium access to a vital drug, it could establish new case law on how the MSP should manage requests for high-cost medication in the future. Meanwhile, the country watches the development of a drug litigation symbolizing the universal tension between high-priced medical innovation and the management of limited public resources.